The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ipilimumab for stage unresectable III/IV melanoma: Brazilian experience in an expanded access program.
Rafael Schmerling
Consultant or Advisory Role - Bristol-Myers Squibb
Expert Testimony - Bristol-Myers Squibb
Daniel Herchenhorn
No relevant relationships to disclose
Jose Augusto Rinck
No relevant relationships to disclose
Veridiana Pires De Camargo
Honoraria - Bristol-Myers Squibb
Johnny Camargo
No relevant relationships to disclose
Sergio Vicente Serrano
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Sergio Jobim Azevedo
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Carlos H. Barrios
No relevant relationships to disclose
Jose Getulio Martins Segalla
No relevant relationships to disclose
Vanessa Dybal Bertoni
Honoraria - Bristol-Myers Squibb
Antonio C. Buzaid
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb